Morning Break: Risky EHRs? Hard Sell for Entresto; More Pricey Drugs

(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff
via Morning Break: Risky EHRs? Hard Sell for Entresto; More Pricey Drugs
by

Entresto: Why Is There Silence? We're Not Selling iPhones

(MedPage Today) -- The drug hailed as a true PARADIGM shift, is slow out of the gate
via Entresto: Why Is There Silence? We're Not Selling iPhones
by

ACC: Evolocumab May Be Best Option for Statin Intolerance

(MedPage Today) -- Far greater LDL reduction but still some muscle complaints in GAUSS-3 trial
via ACC: Evolocumab May Be Best Option for Statin Intolerance
by

CardioBrief: How Does HOPE-3 Change Thinking on Primary Prevention?

(MedPage Today) -- Study lends statins strong support but delivers a mixed message for antihypertensives
via CardioBrief: How Does HOPE-3 Change Thinking on Primary Prevention?
by

ACC: Looking Beyond Statins in LDL Lowering

(MedPage Today) -- New ACC guidance maps a path
via ACC: Looking Beyond Statins in LDL Lowering
by

PodMed: A Medical News Roundup From Johns Hopkins (with audio)

(MedPage Today) -- This weeks topics include home care and survival, timing of HRT, Lyme disease and long-term antibiotics, and cardiac procedures before surgery
via PodMed: A Medical News Roundup From Johns Hopkins (with audio)
by

D.C. Week: Obama Sets Task Force to Ensure Access to Addiction Tx

(MedPage Today) -- FDA updates its labeling for medical abortion drug mifepristone
via D.C. Week: Obama Sets Task Force to Ensure Access to Addiction Tx
by